Eli Lilly's $2.4 billion bet on genetic medicine has validated the sector's potential. When pharmaceutical giants make moves this big, it often signals the start of an industry acceleration that could benefit the entire ecosystem.
These companies are developing therapies that could revolutionise how we treat diseases - by editing genes and modifying cells directly inside the body. It's the kind of breakthrough technology that could reshape healthcare.
Big pharma companies need these enabling technologies to stay competitive. The Orna acquisition could be just the beginning, with analysts expecting increased takeover activity and strategic partnerships across genetic medicine.
Eli Lilly's massive $2.4 billion acquisition of Orna Therapeutics has validated the potential of circular RNA and in vivo cell engineering. This landmark deal signals that major pharmaceutical companies are willing to pay premium prices for next-generation genetic medicine technologies, potentially triggering increased M&A activity and strategic partnerships across the sector.
This collection focuses on the essential building blocks of genetic medicine - from gene editing tools like CRISPR to RNA synthesis platforms and crucial delivery systems. These companies develop the foundational technologies that enable therapies to modify cells directly within the body, representing a shift from traditional pharmaceutical approaches to precision genetic treatments.
These companies were handpicked by professional analysts as the key players in genetic medicine's value chain. Each represents a critical component - whether gene editing, RNA therapeutics, or delivery mechanisms - that major drugmakers need to advance their genetic medicine pipelines. The selection captures the potential ripple effect from industry validation.
Eli Lilly's $2.4 billion acquisition of Orna Therapeutics signals a major bet on circular RNA and in vivo cell engineering. This theme focuses on the broader ecosystem of companies developing the next-generation platforms and delivery technologies essential for advancing genetic medicine.
This basket's total market capitalisation is 1,030,041.2110000001 and is heavily anchored by a single large-cap holding, which tends to give the basket a concentrated, relatively stable profile. Such large-cap dominance generally reduces volatility and aligns performance more with broader market movements.
LLY: $987.61B
MRNA: $16.39B
CRSP: $4.74B
Get the full story on this Basket. Read our detailed article on its risks and potential.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
Home Depot's recent earnings beat highlights consistent consumer spending on smaller household repair and maintenance projects. This ongoing trend presents promising opportunities for various home improvement retailers and building material suppliers.
+6
Here are a few of the assets in this group. Create an account to unlock the full list.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
If you invested across these assets:
In 12 months it might be worth:
+195.86%
On average, analysts expect assets in this group to grow 195.86% over the next year.
11 of 15 assets in this group are rated Buy by professional analysts.
